/
We are a global biopharmaceutical company dedicated to improving the lives of children and adults with spinal muscular atrophy ( SMA ) and additional rare, severe and debilitating neuromuscular diseases. As a leader in the biology of the transforming growth factor beta ( TGF ) superfamily, our novel understanding of the molecular mechanisms of growth factor activation enabled the development of…
ROIC dropped from -55.25% to -77.11%, capital efficiency is deteriorating. Negative free cash flow of -$301M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (FY)
$0.00
Net Income (TTM)
-$409M
▼ -53.5% YoY
Op. Margin
—
ROIC
-87.10%
▼ -21.9pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$304M
▼ -49.5% YoY
Op. Cash Flow (TTM)
-$303M
▼ -49.3% YoY
Net Debt
-$274M
Net Cash Position
Cash & Equiv.
$480M
Continue Research